跳至主要内容
临床试验/NCT01326390
NCT01326390终止不适用

Impact of C-arm CT in Patients With Decreased Renal Function Undergoing Transhepatic Arterial Chemoembolization (TACE) for the Treatment of Hepato-Cellular Carcinoma

Stanford University1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2010年5月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
13
试验地点
1
主要终点
Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)

研究概览

简要总结

Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must be affected by HCC
  • Patients must have diminished renal function (GFR<60 ml/min/1.73m^2)
  • Patients must be 18 years old or older
  • Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.
  • Ability to understand and the willingness to sign a written informed consent document.

排除标准

  • Subjects under the age of 18
  • Patients currently on dialysis
  • Pregnant women

结局指标

主要结局

Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)

时间窗: 3 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验